Innovations in Product Design and Materials Brighten Outlook for Non-Vascular Stents Market
Changing lifestyles have led to a rise in gastrointestinal diseases, urological problems, glaucoma and other conditions, which necessitate the use of non-vascular stents. The increase in gastro-urological and respiratory morbidities, in particular, demands the use of non-vascular stents as they can help maintain vessel patency. With the accelerating demand for minimally invasive treatments, which cause less pain, enable faster recovery, and involve shorter hospital stays, the non-vascular stent market is likely to witness encouraging growth trends.
New analysis from Frost & Sullivan, Technology Innovations in Non-Vascular Stents, finds that innovations in biodegradable and other materials, unique technological properties of metals and polymers like the capacity to self-expand, and advanced deployment techniques will fuel advances in the non-vascular stents sector.
“Material and technology innovations have enabled the development of specially designed stents that can be used for versatile indications,” noted Technical Insights Industry Analyst Debarati Sengupta. “This has increased the diversity of non-vascular stents applications, the size of the target patient pool, and the confidence among physicians using these products.”
Key concerns for physicians include complications surrounding stent migration due to forces experienced at the sites of implantation and problems associated with stent removal. The lack of evidence regarding the overall safety of newer designs and materials used to develop non-vascular stents will also restrain market development.
As such, the sustained publication of clinical safety information will go a long way in convincing physicians and patients of the safety of non-vascular stents. Physicians and patients must be aware of the latest product developments; for instance, the upcoming introduction of micro-stents in the neural and ophthalmic application segments. Along with this, market participants should efficiently train physicians and surgeons on the way to carry out procedures that require non-vascular stents to boost adoption rates.
The premium price tag that non-vascular stents come with will continue to suppress uptake in the short term. However, technological innovations and material improvements are likely to lower the cost of non-vascular stents in the medium- and long-term.
“Other major issues surrounding the ease of deployment will also lose relevance as advances in non-vascular stents through proprietary technologies gain pace,” concluded Sengupta. “Ultimately, this will result in the enhanced usage of these products in interventional procedures as well.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance